82 FR 44820 - Notice of Non-Competitive, Supplemental Funding Award for Ryan White HIV/AIDS Program, Special Projects of National Significance

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration

Federal Register Volume 82, Issue 185 (September 26, 2017)

Page Range44820-44821
FR Document2017-20544

This non-competitive award will provide Secretary's Minority AIDS Initiative Fund (SMAIF) supplemental funding to the Jurisdictional Approach to Curing Hepatitis C among HIV/HCV Coinfected People of Color--Evaluation and Technical Assistance Center (ETAC), RAND Corporation. This supplemental funding will allow RAND Corporation to provide evaluation and technical assistance to cooperative agreement recipients and subrecipient clinical sites under HRSA-17-047 Curing Hepatitis C among People of Color Living with HIV.

Federal Register, Volume 82 Issue 185 (Tuesday, September 26, 2017)
[Federal Register Volume 82, Number 185 (Tuesday, September 26, 2017)]
[Notices]
[Pages 44820-44821]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-20544]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration


Notice of Non-Competitive, Supplemental Funding Award for Ryan 
White HIV/AIDS Program, Special Projects of National Significance

AGENCY: Health Resources and Services Administration (HRSA), HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This non-competitive award will provide Secretary's Minority 
AIDS Initiative Fund (SMAIF) supplemental funding to the Jurisdictional 
Approach to Curing Hepatitis C among HIV/HCV Coinfected People of 
Color--Evaluation and Technical Assistance Center (ETAC), RAND 
Corporation. This supplemental funding will allow RAND Corporation to 
provide evaluation and technical assistance to cooperative agreement 
recipients and subrecipient clinical sites under HRSA-17-047 Curing 
Hepatitis C among People of Color Living with HIV.

SUPPLEMENTARY INFORMATION: 
    Intended Recipient of the Award: RAND Corporation (U90HA30519).
    Amount of Non-Competitive Award: Up to $250,000 per year for 3 
years (pending availability of future year funding).
    Period of Funding: September 30, 2017, through September 29, 2020.
    CFDA Number: No. 93.928.
    Authority: The Consolidated Appropriations Act, 2017 (Pub. L. 115-
31), Division H, Title II.
    Justification: In fiscal year (FY) 2016, the SMAIF Curing Hepatitis 
C among People of Color Living with HIV initiative was launched through 
three funding opportunities: (1) Jurisdictional Approach to Curing 
Hepatitis C among HIV/HCV Co-infected People of Color--Jurisdictional 
Sites (HRSA-16-189) and (2) Jurisdictional Approach to Curing Hepatitis 
C among HIV/HCV Coinfected People of Color--State Health Departments 
Coordinating Center (HRSA-16-195) to provide HIV primary medical care 
to low income, uninsured, and underserved people living with both HIV 
and hepatitis C virus (HCV); and (3) Jurisdictional Approach to Curing 
Hepatitis C among HIV/HCV Coinfected People of Color--ETAC (HRSA-16-
188) to provide evaluation and technical assistance to the funded 
sites. In FY17, HRSA-17-047 was announced to improve HCV prevention and 
care; improve coordination to linkage and retention in care; and 
enhance capacity of health department

[[Page 44821]]

surveillance systems to monitor HIV/HCV coinfections among low-income 
or underinsured, racial and ethnic minority populations. HRSA-17-047 
recipients and subrecipients will require similar evaluation and 
technical assistance in order to meet the program's goals and 
objectives. Supplemental funding to the existing ETAC is a cost 
effective and efficient solution that will leverage RAND Corporation's 
currently funded infrastructure to include the additional sites funded 
under HRSA-17-047. Further, this supplemental funding will leverage 
RAND's current work by combining and comparing evaluation results 
across all jurisdictions from both initiatives and facilitate the 
streamlining and integration of processes and technical assistance. 
Supplemental funding will also provide opportunities for RAND 
Corporation to create joint learning networks and build on lessons 
learned from the initial cohort of jurisdictional sites currently in 
the second year of implementation. Not issuing this award would result 
in a lack of evaluation and technical assistance for HRSA-17-047 
recipients and subrecipients, which is critical to achieving the 
initiative's goal to cure HCV among HIV/HCV coinfected people of color.

FOR FURTHER INFORMATION CONTACT: Mr. Adan Cajina, Chief, Demonstration 
Evaluation Branch, Office of Training and Capacity Development, 
Division of HIV Domestic Programs, HIV/AIDS Bureau, HRSA, 5600 Fishers 
Lane, 09N108, Rockville, MD 20857, Phone: (301) 443-3180, Email: 
[email protected].

    Dated: September 19, 2017.
George Sigounas,
Administrator.
[FR Doc. 2017-20544 Filed 9-25-17; 8:45 am]
 BILLING CODE 4165-15-P


Current View
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice.
ContactMr. Adan Cajina, Chief, Demonstration Evaluation Branch, Office of Training and Capacity Development, Division of HIV Domestic Programs, HIV/AIDS Bureau, HRSA, 5600 Fishers Lane, 09N108, Rockville, MD 20857, Phone: (301) 443-3180, Email: [email protected]
FR Citation82 FR 44820 

2024 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR